Skip to main
SILK
SILK logo

SILK Stock Forecast & Price Target

SILK Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 42%
Sell 17%
Strong Sell 8%

Bulls say

Silk Road Medical Inc. has exhibited strong growth in its TCAR procedure volumes, achieving an annual growth rate of approximately 20% in early 2024, indicating a solid demand for its innovative treatment for carotid artery disease. The introduction of tapered stents and a new carotid National Coverage Determination (NCD) has contributed to a positive outlook, with vascular surgeons reporting increased carotid referral volumes and an overall improvement in category awareness. Additionally, the company's financial performance demonstrates year-over-year leverage improvement, as well as expectations for continued robust growth reflected in higher revenue forecasts and a favorable market valuation multiple recovery.

Bears say

Silk Road Medical has faced a significant decline in stock performance, with shares dropping 74% year-to-date, raising concerns among investors. The company has lowered its full-year 2023 revenue guidance from $180-184 million to $170-174 million, reflecting a disappointing execution despite initial promise in TCAR volume growth. Additionally, a combination of factors, including a choppy operational landscape and uncertainties surrounding CMS's decision to reopen the carotid National Coverage Determination, has contributed to a negative outlook for the company's financial future.

SILK has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 42% suggest Holding, 17% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Silk Road Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Silk Road Medical Inc (SILK) Forecast

Analysts have given SILK a Hold based on their latest research and market trends.

According to 12 analysts, SILK has a Hold consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Silk Road Medical Inc (SILK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.